Regadenoson myocardial perfusion imaging
| Autor: | Ami E. Iskandrian, Gilbert J. Zoghbi |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Agonist
medicine.medical_specialty Vasodilator stress Radiological and Ultrasound Technology medicine.diagnostic_test business.industry medicine.drug_class Regadenoson Myocardial perfusion imaging Bolus (medicine) Tolerability Anesthesia Internal medicine Stress studies Cardiology Medicine Radiology Nuclear Medicine and imaging business medicine.drug |
| Zdroj: | Imaging in Medicine. 2:395-406 |
| ISSN: | 1755-5205 1755-5191 |
| Popis: | Vasodilator stress myocardial perfusion imaging accounts for approximately half of the stress studies in the USA. Regadenoson, a selective A2A receptor agonist, was recently approved for clinical use by the US FDA. By contrast, compared with adenosine, regadenoson is administered as a single- and fixed-dose bolus, has comparable hyperemic effect and a better tolerability profile. This article will address and highlight the various regadenoson attributes, properties and the preclinical and clinical studies that have been conducted to date. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|